Your session is about to expire
← Back to Search
Photon Therapy
Proton vs. Photon Therapy for Breast Cancer
N/A
Waitlist Available
Led By Alexander Lin, MD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must be proceeding with breast/chest wall and nodal radiation therapy including internal mammary node treatment
Females or males diagnosed with pathologically (histologically) proven invasive mammary carcinoma (ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy with any type of axillary surgery or axillary sampling
Must not have
Any radiation therapy for the currently diagnosed breast cancer prior to randomization
Dermatomyositis with a CPK level above normal or with an active skin rash or scleroderma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether proton therapy or photon therapy is better for treating breast cancer. It will follow patients for side effects, quality of life, and cancer control.
Who is the study for?
This trial is for adults (21+) with non-metastatic breast cancer, regardless of surgery type or breast size. Participants must be planning radiation therapy and have insurance coverage for the treatments tested. People with HIV can join if treated and meet certain health criteria. Excluded are those with prior chest radiation, current metastases, or specific autoimmune conditions.
What is being tested?
The study compares proton therapy to photon therapy in treating locally advanced breast cancer, focusing on long-term heart health, quality of life, and effectiveness in controlling cancer.
What are the potential side effects?
While not specified here, common side effects from radiation therapies like proton and photon may include skin changes at the treatment site, fatigue, mild swelling in the treated area, and a temporary change in breast color.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for radiation therapy on my breast/chest and lymph nodes, including the internal mammary nodes.
Select...
I have been diagnosed with breast cancer and have had surgery to remove it.
Select...
I have non-metastatic breast cancer at stage I, II, III, or loco-regionally recurrent.
Select...
I am 21 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not received radiation for my current breast cancer before joining this study.
Select...
I have dermatomyositis with high CPK levels or an active rash, or I have scleroderma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Effectiveness of proton therapy vs. photon therapy
Secondary study objectives
Disease Control
Long Term Survival
Fatigue
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: PhotonActive Control1 Intervention
Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
Group II: ProtonActive Control1 Intervention
Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
Find a Location
Who is running the clinical trial?
Abramson Cancer Center at Penn MedicineLead Sponsor
413 Previous Clinical Trials
163,976 Total Patients Enrolled
45 Trials studying Breast Cancer
59,649 Patients Enrolled for Breast Cancer
Patient-Centered Outcomes Research InstituteOTHER
573 Previous Clinical Trials
27,077,064 Total Patients Enrolled
7 Trials studying Breast Cancer
1,497,555 Patients Enrolled for Breast Cancer
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
107,275 Total Patients Enrolled
40 Trials studying Breast Cancer
34,075 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- There is clear proof from the doctor or scans that the cancer has spread to other parts of the body.I have had radiation therapy on the same side as my current breast or chest cancer.I have not received radiation for my current breast cancer before joining this study.I am scheduled for radiation therapy on my breast/chest and lymph nodes, including the internal mammary nodes.I have been diagnosed with breast cancer and have had surgery to remove it.I have dermatomyositis with high CPK levels or an active rash, or I have scleroderma.I don't have any other serious illnesses that would stop me from participating in the study.I have non-metastatic breast cancer at stage I, II, III, or loco-regionally recurrent.I have cancer in both breasts and will be considered as having left-sided breast cancer.I have had a lumpectomy and any form of breast reconstruction or none at all.My breast size does not limit my eligibility after lumpectomy.I am HIV positive, on HAART, and my CD4 count is ≥ 200.I had a medical check-up relevant to my condition within the last 90 days.My health insurance will cover the study's treatment, but I can pay for some costs if needed.I am 21 years old or older.I've been mostly able to care for myself in the last 3 months.
Research Study Groups:
This trial has the following groups:- Group 1: Photon
- Group 2: Proton
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger